1Thornsberry C,Jones M E,Hickey M L,et al.Resistance surveillance of Streptococcus pneumoniae, haemophilus influenzae and Moraxella catarrhalis isolated in the United States, 1997 1998[].Journal of Antimicrobial Chemotherapy.1999 被引量：1
2Inoue E,Mitsuhashi S.In vitro antibacterial activity andbeta-lactamase stability of SY5555,a new oral penemantibiotic[].Antimicrobial Agents and Chemotherapy.1994 被引量：1
5Dalhoff A,et al.Beta-lactamase stability of faropenem[J].Chemotherapy,2003,49:229-236. 被引量：1
6Nishivama T,et al.In vitro activity of faropenem against beta-lactamase produing clinical isolates[J].Jpn J Antibiot,2000,53:179-183. 被引量：1
7Dalhoff A,et al.Target affinities of faropenem to and its impact on the morphology of gram-positive and gram-negative bacteria[J].Chemotherapy,2003,49(4):172-183. 被引量：1
8Critchley IA,et al.National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S.Faropenem surveillance study[J].Antimicrob Agents Chemother,2007,51(12):4382-4389. 被引量：1
9Upchurch J,et al.Randomized double-blind study comparing 7-and10-day regimens of faropenem medoxomil with a 10-day cefuroxime axetil regimen for treatment of acute bacterial sinusitis[J].Otolaryngol Head Neck Surg,2006,135(4):511-517. 被引量：1
10Hamasuna R,et al.Treatment of acute uncomplicated cystitis with faropenem for 3 days versus 7 days:multicentre,randomized,open-label,controlled trial[J].J Antimicrob Chemother,2014 Feb 6. 被引量：1
